Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors.

NCT05089266 is registered in ClinicalTrials.gov with Shanghai Cell Therapy Group Co.,Ltd as lead sponsor.

NCT NCT05089266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05089266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors.
Lead sponsor
Shanghai Cell Therapy Group Co.,Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
November 30, 2021
Completion date
January 30, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer